CTIS2024-513766-20-00进行中（未招募）1 期
MAATEO:A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib
Oxcia AB0 个研究点目标入组 25 人开始时间: 2024年4月17日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1.Written informed consent. 2.Age 18-75 years (may be extended to older if deemed fit). 3.The patient has received standard of care treatments and has refractory or relapsed or progressive disease with no suitable standard of care options available. For expansion cohort (Cohort V): Patients can only have received a maximum of 70% of anthracycline lifetime exposure to date of proposed dosing day. 4.Cohorts I-IV: AML, ALL, DLBCL, Burkitt lymphoma, multiple myeloma or high-risk MDS, according to the WHO 2016 criteria. Expansion cohort (Cohort V): AML or MDS according to the ELN 2017 criteria. 5.Life expectancy of at least 8 weeks (as per investigators clinical assessment). 6.ECOG PFS 0-2 7.Patients must have measurable disease by blood or bone marrow or imaging examination. 8.Have a normal left ventricular ejection fraction (LVEF) based on institutional ranges. 9.Adequate hepatic and renal function defined as: a.Total bilirubin < 3 x ULN (does not apply to patients with Gilberts Syndrome). b.AST and ALT = 5 x ULN. c.The calculated GFR is at least 30 ml/min using Cockcroft-Gault method. 10.Platelet count=10 x 109/L. (Can be supported by platelet transfusion) 11.Subject must be able to take oral medication. Negative pregnancy test according to CTFG guidance 2014 for females of child-producing potential.
排除标准
- •1.Age less than 18 years. 2.Less than 4 weeks since stopping previous systemic chemotherapy treatment with the exception of Hydroxyurea, Trophosphamide, oral Cyclophosphamide, ImID or Thioguanine which needs to be stopped 10 x t1/2 prior to Karonudib administration. 3.Less than 1 week since stopping palliative radiotherapy. 4.Less than 2 weeks after surgery except access surgical procedures. 5.Less than 6 months since a clinically significant cardiovascular event such as myocardial infarction, unstable angina, angioplasty, bypass surgery, stroke or TIA. 6.Congestive heart failure NYHA class > II. 7.History of arrhythmias or arrhythmias discovered during the screening period (apart from atrial fibrillation without ventricular tachycardia and premature extra beats). 8.Patients requiring anti-arrhythmic drugs except for stable dose beta-blocking or calcium channel blocking agents. 9.QTc interval >470 ms at baseline (Fridericia correction). 10.Use of Fentanyl (must be stopped at least 1 week prior to initiation of Karonudib). 11.Use of anti-oxidants vitamins and Acetylcysteine (must be stopped within 48 hours of starting treatment with Karonudib). 12.Use of antidepressant medications which are substrate for CYP2D6 (must be stopped at least 3 weeks prior to starting treatment with Karonudib). 13.Any severe acute or chronic medical condition that places the patient at increased risk or interferes with the interpretation of study results. 14.Intracerebral engagement (patient with previously known engagement are eligible provided that there is no evidence of disease progression for a minimum of 8 weeks prior to inclusion. 15.Known acute or chronic infection with hepatitis B or C except for DNA-negative hepatitis B with stable dose anti-viral agents. 16.Known HIV infection. 17.Pregnant or breast-feeding women. 18.Patients with reproductive potential not implementing accepted and effective means of contraception. 19.Participation in any other clinical trial with a pharmaceutical product within 5 x t½, or minimum 1 week, since last dosing of the IMP, whichever is the shorter. 20.Acute promyelocytic leukemia (AML M3). 21.Uncontrolled ongoing systemic or localized infection. 22.Unable to comply with study procedures. 23.Peripheral neurological toxicity CTCAE grade 2 or higher.
研究者
相似试验
进行中（未招募）
1 期
Gene therapy study using a frozen formulation of OTL-103 in patients with Wiskott-Aldrich Syndrome (WAS)Wiskott-Aldrich SyndromeMedDRA version: 20.0Level: PTClassification code 10061598Term: ImmunodeficiencySystem Organ Class: 10021428 - Immune system disordersEUCTR2018-003842-18-ITOrchard Therapeutics Ltd.6
进行中（未招募）
1 期
GENE THERAPY IN CHILDREN WITH RAG1-DEFICIENT SEVERE COMBINED IMMUNODEFICIENCYPatients with severe combined immunodeficiency (SCID) based on a genetic defect in the Recombinase Activating Gene 1 (RAG1)EUCTR2019-002343-14-NLeiden University Medical Center5
招募中
2 期
PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELL GENE THERAPY FOR RAG1-DEFICIENT SEVERE COMBINED IMMUNODEFICIENCYRAG1 SCID10021460severe combined immunodeficiencyNL-OMON54570eids Universitair Medisch Centrum3
尚未招募
Unknown
A Study of Blood Cells Count in 6 Months to 18 Years Old PatientsCTRI/2023/12/060609Dr Kaushal Vasudev Vanjani
已完成
不适用
Phase 2 trial for hematological CR patients of AML after chemotherapy.Acute myeloid leukemiaJPRN-UMIN000015870Osaka University60